Pulmonary Rehabilitation Accelerates the Recovery of Pulmonary Function in Patients With COVID-19

Pengfei Zhu1†, Zhengchao Wang2†, Xiaomi Guo3†, Zhiyong Feng4, Chaochao Chen4, Ai Zheng4, Haotian Gu5*‡ and Yu Cai4*‡

1 Department of Cardiology, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 2 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 3 Department of Ultrasound, Wuhan Asia General Hospital, Wuhan, China, 4 Department of Rehabilitation, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 5 British Heart Foundation Centre of Research Excellence, King’s College London, London, United Kingdom

Objectives: To evaluate the effect of in-hospital pulmonary rehabilitation (PR) on short-term pulmonary functional recovery in patients with COVID-19.

Methods: Patients with COVID-19 (n = 123) were divided into two groups (PR group or Control group) according to recipient of pulmonary rehabilitation. Six-min walk distance (6MW), heart rate (HR), forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), and diffusing capacity of the lung for carbon monoxide (DLCO), and CT scanning were measured at the time of discharge, 1, 4, 12, and 24 weeks.

Results: At week one, both PR group and Control group showed no significant changes in pulmonary function. At 4 and 12 weeks, 6MW, HR, FVC, FEV1, and DLCO improved significantly in both groups. However, the improvement in the PR group was greater than the Control group. Pulmonary function in the PR group returned to normal at 4 weeks [FVC (% predicted, PR vs. Control): 86.27 ± 9.14 vs. 78.87 ± 7.55; FEV1 (% predicted, PR vs. Control) 88.76 ± 6.22 vs. 78.96 ± 6.91; DLCO (% predicted, PR vs. Control): 87.27 ± 6.05 vs. 89.96 ± 5.37] compared to 12 weeks in the control group [FVC (% predicted, PR vs. Control): 90.61 ± 6.05 vs. 89.96 ± 4.05; FEV1 (% predicted, PR vs. Control): 91.99 ± 8.73 vs. 88.57 ± 5.37]. Residual lesions on CT disappeared at week 4 in 49 patients in PR group and in 28 patients in control group (p = 0.0004).

Conclusion: Pulmonary rehabilitation could accelerate the recovery of pulmonary function in patients with COVID-19.

Keywords: pulmonary training, corona virus disease 2019, pulmonary function, pulmonary rehabilitation, 2019-nCoV
INTRODUCTION

Corona Virus Disease (COVID-19) caused by a novel coronavirus named as Severe Acute Respiratory Syndrome (SARS)-CoV (Corona Virus)-2 has been rapidly occurring the world and is not completely controlled till now (1, 2). Transmissions through fecal-oral route and ocular are also considered to be possible while evidences are not sufficient till now (3, 4). All age groups are susceptible to SARS-CoV-2, while the elderlies and people with underlying diseases are more likely to develop severe conditions such as severe pneumonia and respiratory failure in a short period of time (2). The therapeutic principles of COVID-19 include general treatment (vital sign monitoring, mechanical ventilation, etc.), drug therapy (anti-infection drugs, traditional Chinese medicine, etc.), pulmonary rehabilitation (PR), nutrition management and mental support.

Pulmonary rehabilitation, as a comprehensive intervention including exercise training, education and behavioral changes that aims to improve the physical and psychological condition in patients with respiratory disease and to promote high long-term quality of life. It has also been confirmed to be an important part of the integrated care strategy for chronic obstructive pulmonary disease (COPD) (5, 6). Its positive effects in preoperative pulmonary rehabilitation were also discovered including reducing the sensation of dyspnea, reducing muscle strength loss associated with dyspnea, and improving psychologic states (7). As for infectious disease of respiratory system, Hsieh et al. (8) found that survivors of acute respiratory distress syndrome (ARDS) caused by influenza A (H1N1) who received pulmonary rehabilitation for 2 months had improved pulmonary function, exercise capacity, and quality of life.

Therefore, the aim of present study was to evaluate the effect of in-hospital pulmonary rehabilitation on short-term pulmonary functional recovery in patients with COVID-19.

METHODS

Patients and Data Collection

We conducted a perspective observational study in patients with COVID-19.

Participants were recruited from Puai Hospital, Wuhan Forth Hospital and Huazhong University of Science and Technology, and were divided into two groups according to whether patients received in-hospital pulmonary rehabilitation. Patients who underwent in-hospital pulmonary rehabilitation were based on the clinical judgements by attending physicians. No patients were directly involved in the design, planning and conception of this study. Inclusion criteria were: (1) patients with COVID-19; (2) able to receive pulmonary rehabilitation; (3) no co-infection of other pathogen; (4) sign the informed consent. Exclusion criteria include: (1) suffering from high blood pressure, diabetes, or other chronic or basic diseases; (2) COVID-19 recurrence during the follow-up period. (3) infection of other pathogen during the follow-up period. (4) pregnancy before or during the follow-up period. Data were collected at the time of discharge and 1, 4, 12, 24 weeks after discharge. The study was approved by Chinese Clinical Trial Registry (ChiCTR2000031751).

Pulmonary Rehabilitation

In the PR group, all patients underwent a standardized rehabilitation scheme (ref) when their clinical condition was stable and capable of PR. Detailed PR protocol as follow: (1) allow patients to maintain regular movement, such as chest expansion and ambulation, in the isolation ward for at least 1 h per day while monitoring heart rate and respiratory rate during movement to avoid overexertion in terms of heart and lung function; (2) provide respiratory control training: Help the patients sit in an upright position to avoid orthopnea. If the patients could not sit upright, lift the head of bed by 60 degrees. Let the patients relax their shoulder muscles by placing one hand on the chest and the other on the abdomen, instruct the patients to deeply breathe in through their nose and breathe out through their mouth to expand the lower chest. (3) pursed lip breathing: Keep the same patient position as with respiratory control. Let the patients breathe in through their nose, hold their breath for 2 s, then deeply breathe out using their abdomen for 3–5 s with their mouth pursed as if they are whistling; this increases the expiratory resistance and prolongs the expiratory time. For (2) and (3) above, the patients were trained repeatedly for 10–15 min each and 4 times per day. The patients could train along with light music if possible. If any discomfort occurred, the training should be stopped immediately.

Outcome Measures

Six-min walk distance (6MW), Heart rate (HR), forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), and Diffusing capacity of the lung for carbon monoxide (DLCO) were measured. CT scanning was conducted at discharge, 4, and 24 weeks. FVC and FEV1 were measure using spirometry. Spirometry was performed using the Medical Graphics CPXD (Minneapolis, MN, US). Diffusing capacity of the lung for carbon monoxide (DLCO) were assessed using the rebreathe technique and a mass spectrometer (Perkin Elmer, St. Louis, MO, USA) as previously described (9, 10). CT scan was conducted using a 64-slice spiral CT machine (NeuSoft, NeuViz64). The CT images was evaluated by two experienced imaging clinicians. If their opinions were different, a third clinician was invited to make the final decision.

Statistical Analysis

Statistical analysis was completed using SPSS 21.0. Baseline differences between groups were analyzed by Student’s t-test for continuous data and by the χ2 test for categorical data. Continuous data are expressed as the means ± SDs, and the normality of distribution was tested by a QQ plot. The data were analyzed using Student’s t-test and repeated measures analysis of variance (ANOVA). As for repeated measures ANOVA, post-hoc test of p-value was adopted by Bonferroni correction and effect size was expressed as eta-square. A value of $p < 0.05$ was considered statistically significant. Because of a small sample size, p-valued between 0.05 and 0.1 was marked with specific value.
RESULTS

A total of 158 participants were screened between February 1st 2020 to March 31st 2020, out of whom 20 patients were excluded because of not meeting the inclusion criteria or declined to participate in this study (Figure 1). Fifteen participants were lost to follow-up before 4 weeks follow-up. Baseline demographics were shown in Tables 1–3.

6MW and HR were shown in Table 4. At the time of discharge, 6MW distance in PR group was longer than the Control group and the HR was lower than the Control group, but did not reach significant. At the time of week 1 and 4, there were significant improvements of 6MW and HR in PR group compared to those at the time of discharge (week 1: 495.88 ± 34.67 vs. 470.83 ± 35.70 p < 0.05 and 83.24 ± 8.46 vs. 97.05 ± 14.24 p < 0.001; week 4: 557.94 ± 38.44 vs. 514.22 ± 43.47 p < 0.01 and 78.59 ± 6.73 vs. 88.61 ± 9.37 p < 0.001). However, in the Control group, only an improvement of 6MW was found at 4 weeks and was smaller than the PR group. At 12 and 24 weeks, 6MW and HR were similar in two groups.

The measurements of FVC and FEV1 is shown in Table 5. At the time of discharge and week 1, FEV1 in the PR group was significantly larger than that in the Control group. There was no significant difference in FVC between the two groups at week 1 (2.05 ± 0.26 vs. 1.91 ± 0.21, p = 0.096). Although FVC and FEV1 improved significantly in both groups, there was greater improvement in the PR groups than the Control group at week 4. FEV1 and FVC in the PR group exceeded 80% of predicted values at 4 weeks [FVC (% predicted): 86.27 ± 9.14 vs. 78.87 ± 7.55, p < 0.05; FEV1 (% predicted) 88.76 ± 6.22 vs. 78.96 ± 6.91, p < 0.001]. At 12 and 24 weeks, there were no significant difference in FEV1 and FVC between two groups and FEV1 and FVC reached 90% of predicted values. There was no significant change in FEV1 to FVC ratio during the entire follow-up period.

### TABLE 1 | General characteristics in PR and control groups.

|                      | PR Group (n = 63) | Control Group (n = 60) | p-value |
|----------------------|-------------------|------------------------|---------|
| Age (years)          | 36.59 ± 7.01      | 35.47 ± 7.58           | 0.40    |
| Gender               |                   |                        |         |
| Male                 | 34                | 29                     | 0.53    |
| Female               | 29                | 31                     |         |
| Blood pressure (mmHg, at discharge) |                   |                        |         |
| Systolic pressure    | 116.3 ± 4.4       | 115.8 ± 5.2            | 0.57    |
| Diastolic pressure   | 78.7 ± 3.2        | 78.1 ± 3.5             | 0.32    |
| Weight (kg, at discharge) | 62.4 ± 11.3     | 64.0 ± 10.9            | 0.43    |
| Height (cm, at discharge) | 167.6 ± 13.2    | 167.8 ± 12.9           | 0.93    |
| Personal habits      |                   |                        |         |
| Smoking              | 7 (11.1)          | 9 (15.0)               | 0.52    |
| Drinking             | 4 (6.3)           | 3 (5.0)                | 0.75    |
| Education            |                   |                        | 0.66    |
| Junior high school or below | 12               | 9                      |         |
| High school or vocational school | 19            | 24                     |         |
| College degree       | 16                | 17                     |         |
| Bachelor degree      | 12                | 8                      |         |
| Postgraduate degree or above | 4               | 2                      |         |

PR, pulmonary rehabilitation.
DLCO was shown in Table 6. At the first week after discharge, no improvements were discovered in DLCO. Meanwhile, the DLCO of PR group was higher than Control group (19.65 ± 2.12 vs. 17.03 ± 1.94, p < 0.01). Significant improvements were discovered at 4 weeks, while level of DLCO in the PR group was higher than the Control group [DLCO (% predicted): 87.27 ± 6.20 vs. 77.78 ± 5.85, p < 0.001]. At 12 and 24 weeks, DLCO reached normal level and had no significantly differences between two groups.

As shown in Figure 2, in the PR group, little parenchymal bands with group-glass opacity were observed at the time of discharge in all patients. The lesions of 49 patients (77.8%) in PR group basically disappeared at 4 weeks follow-up and no changes were discovered at 24 weeks. The CT images of 60 patients (95.2%) in PR group were basically normal at 24 weeks. PR Group basically disappeared at 4 weeks follow-up and no changes were discovered at 24 weeks. The CT images of 56 patients (93.3%, p = 0.65 vs. PR group) in control group were basically normal at 24 weeks.

DISCUSSION

The main physiological change in patient recovery from COVID-19 is poorer cardio-pulmonary function, and lower FVC, FEV1, and DLCO. Meanwhile most of the values of FEV1/FVC were still abnormal. The main imaging changes from CT scanning were little parenchymal bands with residual group-glass opacity. As a result, the pathologic changes in the lung of patients after discharge might be: (1) residual unabsorbed exudative lesion; (2) mild lung fibrosis. These changes result in the functional disorders include: (1) decreasing in lung capacity; (2) decreasing in lung compliance; (3) decreasing in diffusion function. However, all impairments disappeared within 12 weeks, which means the pathological and functional changes are reversible.

The residual lesions of lung function are not rarely in viral pneumonia. Studies have discovered that survivors from SARS had significantly impaired pulmonary function, limited physical and psychology function, and reduced life quality (11, 12). Regarding influenza A virus H1N1, a study found that over half of these patients had signs of more severe abnormal pulmonary function, including diffusion disorders and small airway dysfunction, 1 year after discharge (13). From our results, we found that the residual lesions of lung function caused by SARS-CoV-2 is relatively short-term and reversible. It might attribute to the relatively lower virulence of the virus or the participants we included were not severe and critical.

Pulmonary rehabilitation is a comprehensive intervention that includes but is not limited to exercise training, education and behavioral changes with the aim to improve the physical and psychological conditions of people with respiratory disease.
### TABLE 4 | Six-min walk distance and heart rate.

|                | Discharge | 1 week | 4 weeks | 12 weeks | 24 weeks |
|----------------|-----------|--------|---------|----------|----------|
| **6MW (m)**    |           |        |         |          |          |
| PR group       | 462.12 ± 31.61 | 496.88 ± 34.67* | 557.94 ± 38.44† | 584.41 ± 20.12† | 598.71 ± 22.38†′ |
| Control group  | 448.56 ± 31.10 | 470.83 ± 35.70 | 514.22 ± 43.47†† | 573.11 ± 29.20†† | 590.33 ± 19.88†† |
| PR vs. control | *p < 0.05, ηp² = 0.932, p_group < 0.05, ηp²_group = 0.124, p_min=group < 0.001, ηp²_min=group = 0.168 |
| **HR (beats/min)** |           |        |         |          |          |
| PR group       | 90.71 ± 9.30  | 83.24 ± 8.48* | 78.59 ± 6.73* | 76.06 ± 6.09† | 76.06 ± 6.09† |
| Control group  | 97.44 ± 10.39 | 97.05 ± 14.24 | 88.61 ± 9.37  | 78.61 ± 9.37†† | 77.00 ± 6.16†† |
| PR vs. control | *p = 0.052, ηp² = 0.778, p_group < 0.05, ηp²_group = 0.143, p_min=group < 0.001, ηp²_min=group = 0.332 |

PR, pulmonary rehabilitation; 6MW, 6-min walk distance; HR, heart rate.

P-value of PR vs. Control was from Student’s t-test between two groups.
P-value of the comparison between different times was from post-hoc test with Bonferroni correction for multiple comparisons [C5(2)]: *p < 0.05/10 vs. discharge; †p < 0.05/10 vs. 1 week; ††p < 0.05/10 vs. 4 weeks.

### TABLE 5 | Forced vital capacity and forced expiratory volume in 1 s.

|                | Discharge | 1 week | 4 weeks | 12 weeks | 24 weeks |
|----------------|-----------|--------|---------|----------|----------|
| **FVC (L)**    |           |        |         |          |          |
| PR group       | 2.05 ± 0.26 | 2.11 ± 0.29 | 2.75 ± 0.30† | 2.89 ± 0.22† | 2.95 ± 0.15† |
| Control group  | 1.91 ± 0.21 | 2.02 ± 0.19 | 2.51 ± 0.20† | 2.66 ± 0.12†† | 2.91 ± 0.10†† |
| PR vs. control | *p = 0.098, ηp² = 0.947, p_group = 0.053, ηp²_group = 0.109, p_min=group < 0.005, ηp²_min=group = 0.295 |
| **FEV₁ (L)**   |           |        |         |          |          |
| PR group       | 1.52 ± 0.12 | 1.54 ± 0.14 | 2.12 ± 0.11† | 2.25 ± 0.10†† | 2.29 ± 0.14†† |
| Control group  | 1.43 ± 0.11 | 1.48 ± 0.09 | 1.88 ± 0.12† | 2.24 ± 0.10†† | 2.31 ± 0.13†† |
| PR vs. control | *p < 0.05, ηp² = 0.986, p_group < 0.05, ηp²_group = 0.102, p_min=group < 0.005, ηp²_min=group = 0.295 |
| **FEV₁ (% predicted)** |           |        |         |          |          |
| PR group       | 63.62 ± 5.82 | 64.54 ± 7.11 | 88.76 ± 6.22† | 94.06 ± 0.43† | 95.83 ± 5.29†† |
| Control group  | 59.81 ± 4.94 | 61.58 ± 5.29 | 78.96 ± 6.91† | 93.85 ± 5.61†† | 97.01 ± 5.79†† |
| PR vs. control | *p < 0.05, ηp² = 0.938, p_group < 0.05, ηp²_group = 0.152, p_min=group < 0.005, ηp²_min=group = 0.499 |
| **FEV₁/FVC (%)** |           |        |         |          |          |
| PR group       | 74.73 ± 5.89 | 73.67 ± 8.08 | 77.70 ± 6.70 | 78.15 ± 5.96 | 77.82 ± 4.25 |
| Control group  | 74.99 ± 5.55 | 74.39 ± 6.63 | 75.32 ± 5.43 | 78.30 ± 4.37 | 78.55 ± 5.35 |
| PR vs. control | *p < 0.05, ηp² = 0.565, p_group < 0.05, ηp²_group = 0.004, p_min=group < 0.005, ηp²_min=group = 0.210 |

PR, pulmonary rehabilitation; FVC, forced vital capacity; FEV₁, forced expiratory volume in 1 s.
P-value of PR vs. Control was from Student’s t-test between two groups.
P-value of the comparison between different times was from post-hoc test with Bonferroni correction for multiple comparisons [C5(2)]: *p < 0.05/10 vs. discharge; †p < 0.05/10 vs. 1 week; ††p < 0.05/10 vs. 4 weeks.
and promote long-term quality of life (6). Previous studies have confirmed the positive effects of pulmonary rehabilitation on pulmonary diseases such as COPD and H1N1 pneumonia (8, 12, 14). Besides, pulmonary rehabilitation has been proved to benefit the lung function and life quality in interstitial lung diseases such as idiopathic pulmonary fibrosis and interstitial pneumonias (15–17). Based on clinical practice, the program of pulmonary mainly contained three aspects: (1) physical training, (2) respiratory training, and (3) psychological regulation. Therefore, there are three main benefits of PR: (1) improve the patients’ exercise capacity, (2) improve the patients’ pulmonary function, and (3) improve the patients’ psychological state. During the whole follow-up from the time of discharge to 24 weeks later, we can find that the pulmonary function of PR group was basically normal at 4 weeks, while Control group was basically normal at 12 weeks. As a result, the pulmonary rehabilitation could be another limitation for this research.

Because of the flexibility, feasibility and low cost, pulmonary rehabilitation could be a relatively practical way to improve patient condition. Most of patients suffered from COVID-19 are mild and common type, which makes it easy to carry out pulmonary rehabilitation. As for critical patient, whether, when, and how to carry out pulmonary rehabilitation should be further considered. Moreover, the intensity of training relies on the patients’ condition; hence, the therapists should pay more attention each patient’s vital signs and subjective feelings to not only maximize the effectiveness of the training but also avoid adverse events.

The main limitation of our study is that we only reported the results of 24 weeks follow-up, whether COVID-19 have sequela in respiratory system or other systems should be further studied.

On the other hand, the characteristics of socio-economic of patients might affect patients’ choice for accepting pulmonary rehabilitation, which might also lead to a better recovery. However, the socio-economic data were not available, which could be another limitation for this research.

In conclusion, pulmonary rehabilitation could accelerate the recovery of pulmonary function for COVID-19 patients.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
REFERENCES

1. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. (2020) 395:514–23. doi: 10.1016/S0140-6736(20)30154-9

2. Chen ZM, Fu JF, Shu Q, Chen YH, Hua CZ, Li FB, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatrics. (2020) 16:240–6. doi: 10.1007/s12519-020-00345-5

3. Zhang H, Kang Z, Gong H, Xu D, Wang J, Li Z, et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. bioRxiv. 2020.2001.2030.927806 (2020). doi: 10.1101/2020.01.30.927806

4. Lu CW, Liu XF, Jia ZF. 2019-nCoV transmission through the ocular surface must not be ignored. Lancet. (2020) 395:e39. doi: 10.1016/S0140-6736(20)30313-5

5. Spruit MA. Pulmonary rehabilitation. Eur Respir Rev. (2014) 23:55–63. doi: 10.1183/09059180.0008010

6. Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, et al. An official American thoracic society/european respiratory society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. (2013) 188:e13–64. doi: 10.1164/rccm.201309-1634ST

7. Pehlivn E, Balci A, Kilic L, Kadakal F. Preoperative pulmonary rehabilitation for lung transplant: effects on pulmonary function, exercise capacity, and quality of life; first results in Turkey. Exp Clin Transp. (2018) 16:455–60. doi: 10.6002/ect.2017.0042

8. Hsieh MJ, Lee WC, Cho HY, Wu MF, Hu HC, Kao KC, et al. Recovery of pulmonary functions, exercise capacity, and quality of life after pulmonary rehabilitation in survivors of ARDS due to severe influenza A (H1N1) pneumonitis. Influenza Respir Viruses. (2018) 12:643–8. doi: 10.1111/irv.12566

9. Snyder EM, Johnson BD, Beck KC. An open-circuit method for determining lung diffusing capacity during exercise: comparison to rebreathe. J Appl Physiol. (2005) 99:1985–91. doi: 10.1152/japplphysiol.00348.2005

10. Wheatley CM, Baker SE, Daines CM, Phan H, Martinez MG, Morgan WJ, et al. Influence of the Vibrating Acoustic Percusor on pulmonary function and sputum expectoration in individuals with cystic fibrosis. Thor Adv Respir Dis. (2018) 12:1753466618770997. doi: 10.1177/1753466618770997

11. Ngai JC, Ko FW, Ng SS, To KW, Tong M, Hui DS. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respiriology. (2010) 15:543–50. doi: 10.1111/j.1440-1843.2010.01720.x

12. Herridge MS, Tansey CM, Matte A, Tomlinson G, Diaz-Grandelos N, Cooper A, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. (2011) 364:1293–304. doi: 10.1056/NEJMoa1011802

13. Liu W, Peng L, Liu H, Hua S. Pulmonary function and clinical manifestations of patients infected with mild Influenza A virus subtype H1N1: a one-year follow-up. PLoS ONE. (2015) 10:e0133698. doi: 10.1371/journal.pone.0133698

14. Carreiro A, Santos J, Rodrigues F. Impact of comorbidities in pulmonary rehabilitation outcomes in patients with chronic obstructive pulmonary disease. Rev Port Pneumol. (2013) 19:106–113. doi: 10.1016/j.rppneum.2012.12.001

15. Dowman L, Hill CI, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. (2014) Cd006322. doi: 10.1002/14651858.CD006322.pub3

16. Vainshelboim B, Oliveira J, Yehoshua L, Weiss I, Fox BD, Fruchter O, et al. Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis. Respir. (2014) 88:378–88. doi: 10.1159/000367899

17. Yu X, Li X, Wang L, Liu R, Xie Y, Li S, et al. Pulmonary rehabilitation for exercise tolerance and quality of life in IPF patients: a systematic review and meta-analysis. BioMed Res Int. (2019) 2019:8498603. doi: 10.1155/2019/8498603

FUNDING

This study was funded by National Natural Science Foundation of Wuhan (Grant Nos. WX18Q21 and WX19Q24); Health commission of Hubei Province scientific research project (Grant No. WJ2019H371); and The National Natural Science Foundationof Hubei (Grant No. 2019CF8806). We acknowledge the financial support from the National Institute for Health Research, UK (ICA-CL-2018-04-ST2-012) to HG and by British Heart Foundation, UK (PG/19/23/34259) to HG.

ACKNOWLEDGMENTS

We are grateful for all our colleagues for their support of the present study. We are also grateful to the many front-line medical staffs for their dedication in the face of this outbreak, despite the potential threat to their own lives and the lives of their families.